![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Abbott |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002223 |
The purpose of this study is to determine how many HIV-infected patients continue taking ritonavir/indinavir combination after having taken indinavir three times a day as part of their anti-HIV drug therapy. This study also examines the safety and effectiveness of the ritonavir/indinavir combination.
Condition | Intervention |
---|---|
HIV Infections |
Drug: Indinavir sulfate Drug: Ritonavir |
Study Type: | Interventional |
Study Design: | Treatment, Safety Study |
Official Title: | Ritonavir (ABT-538)/Indinavir Combination Treatment in HIV-Infected Patients Previously Receiving Indinavir 800 Mg TID |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
Any condition that in the opinion of the investigator may obscure proper observation of the safety or activity of the treatment regimens used in this study.
Concurrent Medication:
Excluded:
Patients with the following prior conditions are excluded:
Prior Medication:
Excluded:
Prior treatment with ritonavir.
Risk Behavior:
Excluded:
History of active substance abuse (i.e., recreational drugs or alcohol).
Included:
- Indinavir 800 mg three times a day plus unspecified nucleosides for at least 3 months.
United States, California | |
AIDS Healthcare Foundation | |
Los Angeles, California, United States, 90027 | |
Tower Infectious Diseases | |
Los Angeles, California, United States, 90048 | |
United States, Florida | |
Goodgame Med Ctr / Central Florida Research Initiati | |
Maitland, Florida, United States, 32751 | |
Urgent Care Ctr / North Broward Hosp District | |
Fort Lauderdale, Florida, United States, 33316 | |
United States, New York | |
Mount Sinai Med Ctr | |
New York, New York, United States, 10029 | |
United States, Pennsylvania | |
Stephen Hauptman | |
Philadelphia, Pennsylvania, United States, 19107 |
Study ID Numbers: | 245E, M98-823 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002223 |
Health Authority: | United States: Food and Drug Administration |
Drug Therapy, Combination Adolescent Behavior HIV Protease Inhibitors Ritonavir Indinavir |
Virus Diseases Sexually Transmitted Diseases, Viral Indinavir Ritonavir HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
Anti-Infective Agents RNA Virus Infections HIV Protease Inhibitors Slow Virus Diseases Anti-HIV Agents Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Protease Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections |